test de sécrétion d'un antigène vaccinal par le système de sécrétion de type III, p.69 ,
Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011. ,
DOI : 10.3322/caac.20107
Immunotherapy of cancer in 2012, CA: A Cancer Journal for Clinicians, vol.102, issue.suppl 18, pp.309-344, 2012. ,
DOI : 10.3322/caac.20132
The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc. R. Soc. Med, vol.3, pp.1-48, 1910. ,
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine, Clinical Cancer Research, vol.17, issue.11, pp.3520-3526, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-3126
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, New England Journal of Medicine, vol.363, issue.5, pp.411-433, 2010. ,
DOI : 10.1056/NEJMoa1001294
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-70, 2011. ,
DOI : 10.1126/science.1203486
Cancer immunotherapy comes of age, Nature, vol.9, issue.7378, pp.480-489, 2011. ,
DOI : 10.1038/nature10673
Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-52, 1998. ,
DOI : 10.1038/32588
Dendritic cells as therapeutic vaccines against cancer, Nature Reviews Immunology, vol.10, issue.4, pp.296-306, 2005. ,
DOI : 10.1007/s00262-003-0429-0
Taking dendritic cells into medicine. Nature, Sep, vol.27449, issue.7161, pp.419-445, 2007. ,
Origin and development of dendritic cells, Immunological Reviews, vol.17, issue.1, pp.45-54, 2010. ,
DOI : 10.1111/j.0105-2896.2009.00879.x
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors, Annual Review of Immunology, vol.23, issue.1, pp.275-306, 2005. ,
DOI : 10.1146/annurev.immunol.23.021704.115633
Cancer immunotherapy via dendritic cells, Nature Reviews Cancer, vol.29, issue.4, pp.265-77 ,
DOI : 10.1038/nrc3258
The Dorsoventral Regulatory Gene Cassette sp??tzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults, Cell, vol.86, issue.6, pp.973-83, 1996. ,
DOI : 10.1016/S0092-8674(00)80172-5
Toll-like receptor signalling, Nature Reviews Immunology, vol.303, issue.7, 2004. ,
DOI : 10.1038/nri1391
Toll-like receptors and innate immunity, Nature Reviews Immunology, vol.274, issue.2, pp.135-180, 2001. ,
DOI : 10.1038/35100529
Toll-like receptor control of the adaptive immune responses, Nature Immunology, vol.169, issue.10, pp.987-95, 2004. ,
DOI : 10.1126/science.1076071
Opinion: Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, Nature Reviews Immunology, vol.29, issue.6, pp.469-78, 2004. ,
DOI : 10.1126/science.285.5430.1058
Dendritic cells in a mature age, Nature Reviews Immunology, vol.202, issue.6, pp.476-83, 2006. ,
DOI : 10.1038/nri1845
Targeting human dendritic cell subsets for improved vaccines, Seminars in Immunology, vol.23, issue.1, pp.21-28, 2011. ,
DOI : 10.1016/j.smim.2011.01.004
CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO, Annual Review of Immunology, vol.23, issue.1, pp.975-1028, 2005. ,
DOI : 10.1146/annurev.immunol.22.012703.104538
Cross-presentation by dendritic cells, Nature Reviews Immunology, vol.195, issue.8, pp.557-69, 2012. ,
DOI : 10.1038/nri3254
Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells, Science. Feb, vol.26327, issue.5969, pp.1098-102, 2010. ,
Essentials of Th17 cell commitment and plasticity, Blood, vol.121, issue.13, 2013. ,
DOI : 10.1182/blood-2012-09-378653
A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell???mediated tissue damage, Nature Medicine, vol.59, issue.2, pp.139-184, 2007. ,
DOI : 10.1038/nm1551
TH17 cells in tumour immunity and immunotherapy, Nature Reviews Immunology, vol.8, issue.4, pp.248-56, 2010. ,
DOI : 10.1038/nri2742
Follicular Helper T Cells: Lineage and Location, Immunity, vol.30, issue.3, pp.324-359, 2009. ,
DOI : 10.1016/j.immuni.2009.03.003
A novel subset of T-helper cells: follicular T-helper cells and their markers, Haematologica, vol.95, issue.3, pp.356-364, 2010. ,
DOI : 10.3324/haematol.2009.019133
Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity, Jul, vol.1829, issue.1, pp.138-187, 2008. ,
Basic principles of tumor-associated regulatory T cell biology, Trends in Immunology, vol.34, issue.1, pp.33-40 ,
DOI : 10.1016/j.it.2012.08.005
Cytotoxic T lymphocytes: all roads lead to death, Nat. Rev. Immunol, vol.2, issue.6, pp.401-410, 2002. ,
Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol, 2013. ,
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nature Reviews Cancer, vol.208, issue.11, 2011. ,
DOI : 10.1038/nrc3153
Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology, pp.1223-1228, 2012. ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, 2010. ,
DOI : 10.1056/NEJMoa1003466
Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol, pp.23-34, 2011. ,
DOI : 10.1128/cvi.00286-10
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019775
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, issue.5038, pp.1643-1650, 1991. ,
DOI : 10.1126/science.1840703
A listing of human tumor antigens recognized by T cells: March 2004 update, Cancer Immunology, Immunotherapy, vol.29, issue.3, pp.187-207, 2004. ,
DOI : 10.1007/s00262-004-0560-6
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials, The Journal of Immunology, vol.178, issue.4, pp.1975-1984, 2007. ,
DOI : 10.4049/jimmunol.178.4.1975
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, Clinical Cancer Research, vol.15, issue.17, pp.5323-5360, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0737
Heat shock proteins: the ???Swiss Army Knife??? vaccines against cancers and infectious agents, Vaccine, vol.19, issue.17-19, pp.17-192590, 2001. ,
DOI : 10.1016/S0264-410X(00)00492-8
Novel Signal Transduction Pathway Utilized by Extracellular HSP70. ROLE OF Toll-LIKE RECEPTOR (TLR) 2 AND TLR4, Journal of Biological Chemistry, vol.277, issue.17, pp.15028-15062, 2002. ,
DOI : 10.1074/jbc.M200497200
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting, Nature Reviews Immunology, vol.14, issue.10, pp.790-802, 2007. ,
DOI : 10.1038/nri2173
Recent Advances in Design of Immunogenic and Effective Naked DNA Vaccines Against Cancer, Recent Patents on Anti-Cancer Drug Discovery, vol.9, issue.1, 2013. ,
DOI : 10.2174/1574891X113089990037
Plasmid DNA and viral vector-based vaccines for the treatment of cancer, Vaccine, vol.25, issue.2, pp.24-34, 2007. ,
DOI : 10.1016/j.vaccine.2007.05.030
Victories and deceptions in tumor immunology, OncoImmunology, vol.40, issue.1, p.23687, 2013. ,
DOI : 10.4161/onci.20931
Recombinant viral vaccines for cancer, Trends in Molecular Medicine, vol.18, issue.9, pp.564-74, 2012. ,
DOI : 10.1016/j.molmed.2012.07.007
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines, Seminars in Oncology, vol.39, issue.3, pp.296-304, 2012. ,
DOI : 10.1053/j.seminoncol.2012.02.010
Engineering the perfect (bacterial) cancer therapy, Nature Reviews Cancer, vol.42, issue.11, pp.785-94, 2010. ,
DOI : 10.1038/nrc2934
Bacterial vectors for active immunotherapy reach clinical and industrial stages. Hum Vaccin Immunother, pp.1454-1462, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00813376
Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class Irestricted CD8+ T cells following uptake by human APC, J. Immunol. Feb, vol.1172, issue.3, pp.1595-601, 2004. ,
Listeria monocytogenes and Its Products as Agents for Cancer Immunotherapy, Adv. Immunol, vol.113, pp.81-118, 2012. ,
DOI : 10.1016/B978-0-12-394590-7.00004-X
Delivery of epitopes by the Salmonella type III secretion system for vaccine development, Science, vol.281, issue.5376, pp.565-573, 1998. ,
Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens, Infection and Immunity, vol.80, issue.3, pp.1193-202, 2012. ,
DOI : 10.1128/IAI.06056-11
Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment, Bioengineered Bugs, vol.57, issue.4, pp.235-278, 2010. ,
DOI : 10.1158/0008-5472.CAN-08-4855
The type III secretion injectisome, Nature Reviews Microbiology, vol.103, issue.11, pp.811-836, 2006. ,
DOI : 10.1038/nrmicro1526
Protein delivery into eukaryotic cells by type III secretion machines, Nature, vol.281, issue.7119, pp.567-73, 2006. ,
DOI : 10.1038/nature05272
Type III protein secretion systems in bacterial pathogens of animals and plants, Microbiol. Mol. Biol. Rev, vol.62, issue.2, pp.379-433, 1998. ,
Cloning and sequence analysis of a trans-regulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa., Journal of Bacteriology, vol.173, issue.20, 1991. ,
DOI : 10.1128/jb.173.20.6460-6468.1991
Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments, Mol. Microbiol, 1997. ,
Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector, Molecular Therapy, vol.14, issue.5, 2006. ,
DOI : 10.1016/j.ymthe.2006.06.011
URL : https://hal.archives-ouvertes.fr/inserm-00144349
Role of the Type III Secreted Exoenzymes S, T, and Y in Systemic Spread of Pseudomonas aeruginosa PAO1 In Vivo, Infection and Immunity, vol.73, issue.3, 2005. ,
DOI : 10.1128/IAI.73.3.1706-1713.2005
Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages, Molecular Microbiology, vol.95, issue.954-956, pp.76-85, 2001. ,
DOI : 10.1046/j.1365-2958.2001.02368.x
URL : https://hal.archives-ouvertes.fr/hal-00192534
Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system, Infect. Immun, vol.67, issue.11, pp.6164-6171, 1999. ,
Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils, Infection and Immunity, vol.68, issue.5, pp.2916-2940, 2000. ,
DOI : 10.1128/IAI.68.5.2916-2924.2000
A Signaling Network Reciprocally Regulates Genes Associated with Acute Infection and Chronic Persistence in Pseudomonas aeruginosa, Developmental Cell, vol.7, issue.5, pp.745-54, 2004. ,
DOI : 10.1016/j.devcel.2004.08.020
Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon., Journal of Bacteriology, vol.177, issue.15, pp.4427-4463, 1995. ,
DOI : 10.1128/jb.177.15.4427-4436.1995
Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa, BioTechniques, vol.38, issue.1, pp.63-70, 2005. ,
DOI : 10.2144/05381ST01
Optimization of a Type III Secretion System-Based Pseudomonas aeruginosa Live Vector for Antigen Delivery, Clinical and Vaccine Immunology, vol.15, issue.2, pp.308-321, 2008. ,
DOI : 10.1128/CVI.00278-07
URL : https://hal.archives-ouvertes.fr/hal-00381893
Optimal epitope composition after antigen screening using a live bacterial delivery vector, Bioengineered Bugs, vol.47, issue.1, pp.51-60, 2010. ,
DOI : 10.1007/s002620050015
URL : https://hal.archives-ouvertes.fr/hal-00813353
Optimization of Antitumor Immunotherapy Mediated by Type III Secretion System-based Live Attenuated Bacterial Vectors, Journal of Immunotherapy, vol.35, issue.3, pp.223-257 ,
DOI : 10.1097/CJI.0b013e31824747e5
URL : https://hal.archives-ouvertes.fr/hal-00849581
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides, Immunity, vol.1, issue.9, pp.751-61, 1994. ,
DOI : 10.1016/S1074-7613(94)80017-0
Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Semin. Hematol, 2001. ,
Killed but metabolically active vaccines, Current Opinion in Biotechnology, vol.23, issue.6, pp.917-940, 2012. ,
DOI : 10.1016/j.copbio.2012.04.005
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity, Nature Medicine, vol.166, issue.8, pp.853-60, 2005. ,
DOI : 10.1046/j.1365-2958.2002.03072.x
Application of a New Technology to an Old Vector, The Journal of Infectious Diseases, vol.195, issue.8, pp.1203-1214, 2007. ,
DOI : 10.1086/512618
Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009. ,
DOI : 10.1128/IAI.00530-08
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168
???Close-fitting sleeves???: DNA damage recognition by the UvrABC nuclease system, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.577, issue.1-2, pp.92-117, 2005. ,
DOI : 10.1016/j.mrfmmm.2005.03.013
KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity, Journal of Clinical Investigation, vol.118, issue.12 ,
DOI : 10.1172/JCI31350DS1
Live bacterial vaccines--a review and identification of potential hazards, Microbial Cell Factories, vol.5, issue.1, p.23, 2006. ,
DOI : 10.1186/1475-2859-5-23
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen, Nature, vol.406, issue.6799, pp.959-64, 2000. ,
Broad-host-range cre-lox system for antibiotic marker recycling in gram-negative bacteria, BioTechniques, vol.33, issue.5, pp.1062-1069, 2002. ,
Generation of antigen-specific, lacZ-inducible Tcell hybrids, Methods Mol. Biol, vol.156, pp.265-72, 2001. ,
DNA Repair Enzymes, Annual Review of Biochemistry, vol.57, issue.1, pp.29-67, 1988. ,
DOI : 10.1146/annurev.bi.57.070188.000333
A specific 3' exonuclease activity of UvrABC. The EMBO Journal, Jan, vol.1517, issue.2, pp.626-659, 1998. ,
A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy, 2013. ,